Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices, Evident Technologies


Molecular Devices this week introduced the FLIPR Calcium 4 Assay Kit, its next-generation no-wash calcium flux assay.

Molecular Devices first introduced its no-wash, cell-based calcium assay kits for GPCR screening in 1999. The new kit includes a masking technology licensed exclusively from Bayer AG, Molecular Devices said.

The company's kits now include Calcium, Calcium 3, and Calcium 4, all of which are homogenous mix-and-read assays optimized for use with MDCC's FLIPR fluorometric imaging plate readers.

Evident Technologies this week released two new quantum dot tags for use in life science applications: T2-MP EviTag labels and EviFluor conjugates.

The T2-MP EviTags are quantum dot-based, conjugation-ready fluorescent labels with a bioactive surface that features Evident's Molecular Plating surface technology, which help provide improved brightness, photostability, flexibility, and sensitivity, Evident said, They are available with either amine or carboxyl terminal groups, or with a non-functional bioactive surface.

The EviFluors are ready-to-use activated quantum dot conjugates coupled to secondary antibodies and other proteins, Evident said. They are available conjugated to secondary antibodies, streptavidin, and biotin.

EviTag labels are available in colors from Lake Placid Blue (490 nm) to Jonamac deep reds (680 nm); while the EviFluor conjugates are available in Adirondack Green (520 nm), Fort Orange (520 nm), Maple Red-orange (620 nm), and Jonamac (680 nm), Evident said.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.